NeuroMetrix, Inc.

NasdaqCM:NURO Rapport sur les actions

Capitalisation boursière : US$9.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NeuroMetrix Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de NeuroMetrix.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Medical Equipment croissance des bénéfices16.1%
Taux de croissance des recettesn/a
Rendement futur des capitaux propresn/a
Couverture par les analystes

None

Dernière mise à journ/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Seeking Alpha • Oct 20

NeuroMetrix reports Q3 results

NeuroMetrix press release (NASDAQ:NURO): Q3 net loss of $1.6M Revenue of $2M (-4.8% Y/Y).
Seeking Alpha • Sep 23

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Summary DPNCheck is a screening product sold to MA insurers which gives better member health outcomes, lower cost, and increased revenue for MA insurers. The product has consistently grown >20%. Discontinuation of Quell marketing in 2018 is masking the strong, underlying growth in DPNCheck. The result is rev growth is now accelerating. Clean cap structure and balance sheet with $3.24/share which is sufficient to fund the business to profitability. Potential $15/share fair value in 5 years based on 20x FCF. For those who follow small cap med devices, NURO's business is ~85% SMLR and ~15% ZYXI. Thesis Overview The most profitable investments in microcap stocks are made when businesses reach inflection points, then go on to deliver years of organic growth and inflect to profitability. I believe that NeuroMetrix (NURO) is at that turning point. After a long history of losses and shareholder dilution from spending on R&D that didn’t work and attempts to sell medical devices that were not successful, NURO now has a clean capital structure and balance sheet with a proven business that is scaling with strong unit economics. NURO has a promising medical device called DPNCheck, which is used for early disease detection of diabetic polyneuropathy (DPN) and is sold to Medicare Advantage ((MA)) insurers with >80% of revenue from consumables. They are following the same business model as Semler Scientific (SMLR), who built a strong business by showing MA insurers that early disease detection leads to better patient outcomes, lower cost to serve patients, and increased revenue for the MA insurers through appropriately risk-coding patients. DPNCheck launched in 2011 and has grown at a >20% CAGR in recent years to $7.4m revenue in 2022. That >20% organic growth is set to continue indefinitely at ~80% gross margins. Most importantly, DPNCheck’s go-to-market is very efficient because they sell at the top level to UNH and HUM, who then push down to their organization. DPNCheck’s consistent growth and strong unit economics has been masked by NURO’s Quell product which the company sells direct-to-consumer as an over-the-counter (OTC) medical device for pain management. The company created a slick product that works well and grew it to ~$14m of revenue in 2017, but had to spend aggressively on online advertising and TV ads to get that growth (negative unit economics). In 2018, management realized their market efforts were not going to pay off for Quell because the market for TENS-like devices is too crowded, so they stopped advertising. That led to revenue declining to <$2m in 2022, which is now mostly consumable pads that are ordered by customers and paid through credit card (no insurance pay). Management pivoted the strategy for their Quell device to focusing on gaining breakthrough designation by the FDA for patients with Fibromyalgia. 10 million Americans suffer from debilitating pain from Fibromyalgia. Quell may receive FDA clearance for the device for patients with Fibromyalgia in late 2022 and begin marketing to physicians in early 2023. Having a physician prescription means they can pursue insurance reimbursement which results in a much, much higher revenue per device than selling in the highly competitive over-the-counter market. Zynex sells a prescription pain management device, but sells primarily through physical therapists and does not have specific indications or data supporting efficacy, like Quell does. The takeaways are that NURO’s revenue growth is accelerating. After revenue declines in 2018-2020 from unprofitable Quell OTC revenue falling, NURO grew 12% in 2021 and will grow 12% in 2022. I expect revenue growth to accelerate to >20% and maintain that growth for several years, primarily from DPNCheck. After significant losses from Quell advertising, NURO raised highly dilutive preferred capital in the 2016-2018 range (please refer to NURO's form 10-K filings for details). After cleaning up the cap structure, NURO raised over $20m through DRIP equity raises (selling shares directly into the market) in 2020 and 2021 (including some very attractive sales prices last year when the stock price spiked >$10/share). All this leads to an ugly and messy past, in which the share count has gone way up and the stock price way down. However, I believe that evaluating the business based on current facts, shows that NURO is an undervalued med device company that is well capitalized to pursue this growth. The company now has a clean capital structure with 7.1m shares and 0.5m options for management, no debt, no preferred, no warrants, and $23m of cash. I expect NURO to burn $3.8m in 2022, $2.7m in 2023, $1.7m in 2024, and $0.2m in 2025. Then it should start generating cash, with +$2.1m in 2026, +$4.9m in 2027. I model trough cash of $16m in 2025. On profitability, I expect the business will generate $5m of free cash flow in 2027 and be worth 20x FCF plus net cash, which gives a value of $15/share. Studying Semler’s history, once the business crossed $14m in revenue, it inflected to profitability and never looked back. DPNCheck currently has $7.4m in revenue, and I expect it to cross that threshold exiting 2025. SMLR has proven how strong the unit economics are in this business with 37% EBITDA margins in 2Q22. Revenue Mix Shift Well Underway Higher quality, more profitable DPNCheck revenue is replacing negative margin Quell revenue (when including expensive marketing spend in the past). As rev mix continues to shift, the growth will accelerate and the business will reach profitability.
Seeking Alpha • Jul 21

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix press release (NASDAQ:NURO): Q2 GAAP EPS of -$0.17. Revenue of $2.1M (-5.0% Y/Y).
Article d’analyse • May 11

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Jan 19

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Sep 09

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

NeuroMetrix is a medical devices company with three commercialized products. The Company says it was spun off from the Harvard-MIT Division of Health Sciences and Technology in 1996. The Company has active R&D programs to expand into new indications and improve existing technologies.
Article d’analyse • Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, NeuroMetrix...
Article d’analyse • Jan 27

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme NeuroMetrix n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:NURO - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20243-8-7-7N/A
9/30/20244-8-7-7N/A
6/30/20244-8-7-7N/A
3/31/20245-8-7-7N/A
12/31/20236-7-6-6N/A
9/30/20236-6-6-6N/A
6/30/20237-5-6-6N/A
3/31/20238-5-6-6N/A
12/31/20228-4-5-5N/A
9/30/20228-5-4-4N/A
6/30/20228-4-3-3N/A
3/31/20228-3-3-3N/A
12/31/20218-2-2-2N/A
9/30/20218-2-1-1N/A
6/30/20218-1-1-1N/A
3/31/20217-1-1-1N/A
12/31/20207-2-2-2N/A
9/30/20207-3-2-2N/A
6/30/20207-4-4-4N/A
3/31/20208-6-5-5N/A
12/31/20199-4-4-4N/A
9/30/201911-6-4-4N/A
6/30/201913-3-2-2N/A
3/31/201914111N/A
12/31/201816033N/A
9/30/2018170N/A0N/A
6/30/201817-7N/A-3N/A
3/31/201818-11N/A-7N/A
12/31/201717-20N/A-13N/A
9/30/201716-20N/A-13N/A
6/30/201716-17N/A-14N/A
3/31/201714-38N/A-15N/A
12/31/201612-35N/A-15N/A
9/30/201611-43N/A-15N/A
6/30/201610-42N/A-15N/A
3/31/20168-23N/A-14N/A
12/31/20157-21N/A-13N/A
9/30/20156-13N/A-12N/A
6/30/20155-11N/A-10N/A
3/31/20155-12N/A-9N/A
12/31/20146-11N/A-8N/A
9/30/20146-12N/A-7N/A
6/30/20145-11N/A-6N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de NURO est supérieure au taux d'épargne ( 2.8% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de NURO devraient croître plus rapidement que le marché US

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de NURO devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de NURO devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de NURO devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de NURO devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2025/05/01 20:37
Cours de l'action en fin de journée2025/05/01 00:00
Les revenus2024/12/31
Revenus annuels2024/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

NeuroMetrix, Inc. est couverte par 2 analystes. 0 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Andrew FeinH.C. Wainwright & Co.
Anthony VendettiMaxim Group